Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1603

EU103-hIgG1

Home » Antibodies » EU103-hIgG1

Background of EU103-hIgG1

VSIG4 is a type I transmembrane protein with a molecular weight of approximately 45 kDa. It consists of an extracellular domain containing a V-type and a C2-type immunoglobulin domain, a transmembrane domain, and a cytoplasmic domain. The gene is located on the X chromosome and is predominantly expressed in tissue-resident macrophages, including those found in the thymus, liver, adipose tissue, and alveoli. EU103 is a humanized monoclonal antibody targeting V-set and immunoglobulin domain-containing protein 4 (VSIG4), primarily associated with the modulation of tumor-associated macrophages (TAMs) in the cancer microenvironment.

Specifications

Catalog Number:
KB-1603
Antibody Name:
EU103-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
VSIG4
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenvironment
  2. Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures